RANI Therapeutics announces positive initial phase 1a data for rt-114 for the treatment of obesity, with oral bioavailability exceeding matc
RANI Therapeutics announces positive initial phase 1a data for rt-114 for the treatment of obesity, with oral bioavailability exceeding matched subcutaneous dosing Rani Therapeutics - no adverse events attributed to ranipill capsule; treatment-related events were mild - Phase 1B study expected to begin in 2026 with data anticipated in 2027
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.